ELVN vs QURE โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ELVN Captures Institutional Edge (2โ2 Pillars ยท 5โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Enliven Therapeutics, Inc. Common Stock (ELVN) driven by superior Growth & Margin, Momentum & Technical while QURE counters with relative strength in Valuation, Options & Structure. Fundamentally, ELVN trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus QURE at 27.9x Forward P/E and -994.0% operating margin (+40.4% YoY). In options structure, ELVN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro) against QURE sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ELVN | QURE | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.6B | $1.7B | Larger Scale | ELVN |
| Trailing P/E Ratio Valuation | N/M | 27.9x | Lower Multiple | QURE |
| Forward P/E Ratio Valuation | N/M | 27.9x | Lower Multiple | QURE |
| Revenue Growth (YoY) Growth | +0.0% | +40.4% | Higher Growth | QURE |
| Operating Margin (TTM) Profitability | 0.0% | -994.0% | Higher Margin | ELVN |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -16.8% | -89.0% | Higher ROE | ELVN |
| 52-Week Range Position Momentum | 69% ($15โ$62) | 31% ($9โ$52) | Stronger Trend | ELVN |
| Beta / 30D Volatility Risk Regime | 0.96ฮฒ ยท 60% Vol | 0.80ฮฒ ยท 81% Vol | Lower Realized Risk | ELVN |
| Unified Institutional Score Composite Signal | 35.9 / 100 (SELL) | 49.6 / 100 (HOLD) | Higher Composite | QURE |